Roxatidine acetate
Chemical compound / From Wikipedia, the free encyclopedia
Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 80–90% |
Protein binding | 5–7% |
Metabolism | Hepatic deacetylation Minor involvement of CYP2D6 and CYP2A6 |
Elimination half-life | 5–7 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H28N2O4 |
Molar mass | 348.443 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]
It was patented in 1979 and approved for medical use in 1986.[3] It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]